Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2021; 20: 162-167
Редкий случай нодулярной лимфомы Ходжкина с лимфоцитарным преобладанием, развившейся через 5 лет после успешного лечения диффузной крупноклеточной В-клеточной лимфомы
https://doi.org/10.24287/1726-1708-2021-20-1-162-167Аннотация
Нодулярная лимфома Ходжкина с лимфоцитарным преобладанием (НЛХЛП) – В-клеточная лимфома, которая исторически отнесена в группу ходжкинских лимфом, несмотря на особенности клинического течения, лечения и прогноза, а также заметные морфологические, иммуногистохимические отличия от классической лимфомы Ходжкина. В 75% случаев заболевание выявляется на ранних стадиях (I–II по Ann Arbor), имеет индолентное течение и благоприятный прогноз с общей 10-летней выживаемостью > 80%. Несмотря на это, при длительном наблюдении и развитии частых рецидивов может возникать трансформация в диффузную крупноклеточную В-клеточную лимфому (ДКБКЛ) или богатую Т-лимфоцитами/гистиоцитами ДКБКЛ, описаны единичные случаи у детей. В мировой литературе представлены единичные случаи развития НЛХЛП после лечения ДКБКЛ у взрослых, тогда как в детской популяции аналогичных случаев не описано. В данной статье представлен клинический случай ДКБКЛ у ребенка 10 лет, у которого через 5 лет после окончания лечения развилась НЛХЛП. Родители пациента дали согласие на использование информации, в том числе фотографий ребенка, в научных исследованиях и публикациях.
Список литературы
1. Swerdlow S.H., Campo E., Harris N.L. World Health Organization classification of haematopoetic and lymphoidt issues. Lyon: IARC Press; 2017. Рp. 323–5.
2. Nogová L., Reineke T., Brillant C., Sieniawski M., Rüdiger T., Josting A., et al.; German Hodgkin Study Group. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008; 26 (3): 434–9. DOI: 10.1200/JCO.2007.11.8869
3. Xing K.H., Connors J.M., Mansour M.A., Gascoyne R.D. The outcome of advanced stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) compared to classical Hodgkin lymphoma (CHL): a matched pair analysis. ASH Annual Meeting 2012 (abstract 1531)
4. Biasoli I., Stamatoullas A., Meignin V., Delmer A., Reman O., Brice P., et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diff use large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 2010; 116 (3): 631–9. DOI: 10.1002/cncr.24819
5. Mauz-Körholz C., Gorde-Grosjean S., Hasenclever D., Shankar A., Dörffel W., Wallace W.H., et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007; 110 (1): 179–85.
6. Couronné L., Schneider P., Picquenot J.M., Laberge S., Bastard C., Vannier J.P. Refractory nodular lymphocyte predominant Hodgkin lymphoma transformed to T-cell/histiocyte-rich B-cell lymphoma in an adolescent: salvage therapy with allogeneic bone marrow transplantation. J Pediatr Hematol Oncol 2008; 30 (12): 959–62. DOI: 10.1097/MPH.0b013e31818a9564
7. Fan Z., Natkunam Y., Bair E., Tibshirani R., Warnke R.A. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003; 27 (10): 1346–56. DOI: 10.1097/PAS.0b013e318165b0d6
8. Rudiger T., Gascoyne R.D., Jaff e E.S., de Jong D., Delabie J., Müller-Hermelink H.K., et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma. Ann Oncol 2002;13 Suppl 1: 44–51. DOI: 10.1093/annonc/13.s1.44
9. Mauz-Körholz C., Lange T., Hasenclever D., Burkhardt B., Feller A.C., Dörffel W., et al. Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group. Klin Padiatr 2015; 227 (6–7): 314–21. DOI: 10.1055/s-0035-1559664
10. Xu-Monette Z.Y., Li J., Xia Y., Crossley B., Bremel R.D., Miao Y., et al. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune check point blockade and neoantigen-based immunotherapies. J Immunother Cancer 2019; 7 (1): 272. DOI: 10.1186/s40425-019-0730-x
11. Dunn-Walters D., Thiede C., Alpen B., Spencer J. Somatic hypermutation and B-cell lymphoma. Philos Trans R Soc Lond B Biol Sci 2001; 356 (1405): 73–82. DOI: 10.1098/rstb.2000.0751
12. Koh K.N., Yoo K.H., Im H.J., Sung K.W., Koo H.H., Kim H.S. et al. Characteristics and Outcomes of Second Malignant Neoplasms after Childhood Cancer Treatment: Multi-Center Retrospective Survey. J Korean Med Sci 2016; 31 (8): 1254–61. DOI: 10.3346/jkms.2016.31.8.1254
13. Fianchi L., Pagano L., Piciocchi A., Candoni A., Gaidano G., Breccia M., et al. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. Am J Hematol 2015; 90 (5): E80–5. DOI: 10.1002/ajh.23966
Pediatric Hematology/Oncology and Immunopathology. 2021; 20: 162-167
A rare case of nodular lymphocyte predominant Hodgkin lymphoma, which developed 5 years after successful treatment of diffuse large B-cell lymphoma
https://doi.org/10.24287/1726-1708-2021-20-1-162-167Abstract
Nodular lymphocyte predominant Hodgkin lymphoma (NLHLP) – B-cell lymphoma, which has been historically added to the group of Hodgkin's lymphomas, despite the peculiarities of the clinical course, treatment and prognosis, as well as morphological and immunophenotypical differences. In 75% of cases, the disease is detected at early stages (I–II according to Ann Arbor classification), has an indolent course and a favorable prognosis with 10-years an overall survival rate, more than 80%. Despite this, with long-term follow-up and the development of frequent relapses, transformation into diffuse large-cell B-cell lymphoma (DCBCL) or T-lymphocyte/histiocyte-rich DCBCL can occur, isolated cases in children. In the world literature, there are isolated cases of the development of NLHLP after treatment of DCBKL in adults, while among the pediatric population, cases have not been described. This article presents a clinical case of DCBKL in a 10-year-old child who, 5 years after the end of treatment, developed nodular Hodgkin's lymphoma with lymphocytic predominance. The patient's parents agreed to use the information, including the child's photo, in scientific research and publications.
References
1. Swerdlow S.H., Campo E., Harris N.L. World Health Organization classification of haematopoetic and lymphoidt issues. Lyon: IARC Press; 2017. Rp. 323–5.
2. Nogová L., Reineke T., Brillant C., Sieniawski M., Rüdiger T., Josting A., et al.; German Hodgkin Study Group. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008; 26 (3): 434–9. DOI: 10.1200/JCO.2007.11.8869
3. Xing K.H., Connors J.M., Mansour M.A., Gascoyne R.D. The outcome of advanced stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) compared to classical Hodgkin lymphoma (CHL): a matched pair analysis. ASH Annual Meeting 2012 (abstract 1531)
4. Biasoli I., Stamatoullas A., Meignin V., Delmer A., Reman O., Brice P., et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diff use large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 2010; 116 (3): 631–9. DOI: 10.1002/cncr.24819
5. Mauz-Körholz C., Gorde-Grosjean S., Hasenclever D., Shankar A., Dörffel W., Wallace W.H., et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007; 110 (1): 179–85.
6. Couronné L., Schneider P., Picquenot J.M., Laberge S., Bastard C., Vannier J.P. Refractory nodular lymphocyte predominant Hodgkin lymphoma transformed to T-cell/histiocyte-rich B-cell lymphoma in an adolescent: salvage therapy with allogeneic bone marrow transplantation. J Pediatr Hematol Oncol 2008; 30 (12): 959–62. DOI: 10.1097/MPH.0b013e31818a9564
7. Fan Z., Natkunam Y., Bair E., Tibshirani R., Warnke R.A. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003; 27 (10): 1346–56. DOI: 10.1097/PAS.0b013e318165b0d6
8. Rudiger T., Gascoyne R.D., Jaff e E.S., de Jong D., Delabie J., Müller-Hermelink H.K., et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma. Ann Oncol 2002;13 Suppl 1: 44–51. DOI: 10.1093/annonc/13.s1.44
9. Mauz-Körholz C., Lange T., Hasenclever D., Burkhardt B., Feller A.C., Dörffel W., et al. Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group. Klin Padiatr 2015; 227 (6–7): 314–21. DOI: 10.1055/s-0035-1559664
10. Xu-Monette Z.Y., Li J., Xia Y., Crossley B., Bremel R.D., Miao Y., et al. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune check point blockade and neoantigen-based immunotherapies. J Immunother Cancer 2019; 7 (1): 272. DOI: 10.1186/s40425-019-0730-x
11. Dunn-Walters D., Thiede C., Alpen B., Spencer J. Somatic hypermutation and B-cell lymphoma. Philos Trans R Soc Lond B Biol Sci 2001; 356 (1405): 73–82. DOI: 10.1098/rstb.2000.0751
12. Koh K.N., Yoo K.H., Im H.J., Sung K.W., Koo H.H., Kim H.S. et al. Characteristics and Outcomes of Second Malignant Neoplasms after Childhood Cancer Treatment: Multi-Center Retrospective Survey. J Korean Med Sci 2016; 31 (8): 1254–61. DOI: 10.3346/jkms.2016.31.8.1254
13. Fianchi L., Pagano L., Piciocchi A., Candoni A., Gaidano G., Breccia M., et al. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. Am J Hematol 2015; 90 (5): E80–5. DOI: 10.1002/ajh.23966
